用于2型糖尿病的长效GLP1类似物药物

By fusing GLP1 receptor ECD or protective antibodies with GLP1 analogs and utilizing factor Xa protease cleavage site linkers, the problem of rapid degradation of GLP1 analogs was solved, resulting in a longer half-life and more consistent glycemic control.

CN114980916BActive Publication Date: 2026-07-17SERPENTIDE INC
View PDF 17 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SERPENTIDE INC
Filing Date
2021-03-15
Publication Date
2026-07-17

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure HDA0003113175620000011
    Figure HDA0003113175620000011
  • Figure HDA0003113175620000021
    Figure HDA0003113175620000021
Patent Text Reader

Abstract

本发明提供了包含经修饰胰高血糖素样肽(GLP1)多肽的经修饰GLP1融合蛋白及其使用方法。在本发明的各种实施方案中，所述融合蛋白是包含融合至稳定结构域诸如细胞外结构域(ECD)或抗体的经修饰GLP1的GLP1受体激动剂。在一些实施方案中，所述包含经修饰GLP1的融合蛋白可用于治疗或改善血糖障碍诸如肥胖症和糖尿病的症状或适应症。
Need to check novelty before this filing date? Find Prior Art